Categories AlphaGraphs, Health Care, Technology
Medtronic stock gains on strong Q2 results, guidance
Aided by the impressive performance of its key business segments, medical device maker Medtronic (MDT) reported a 6% increase in second-quarter revenues, which also outpaced the estimates. The resultant earnings growth and the company’s upbeat guidance drove up its stock in the early trading hours Tuesday.
![Medtronic Q2 earnings beat estimates Medtronic second quarter 2019 Earnings Infographic](https://cdn.news.alphastreet.com/wp-content/uploads/2018/11/Medtronic-plc-Q2-2019-Earnings-Infographic.png)
Earnings, adjusted for special items, grew 14% to $1.22 per share. Analysts were looking for a slower growth. Meanwhile, net income attributable to shareholders dropped to $1.12 billion or $0.82 per share in the October quarter from $2.02 billion or $1.48 per share in the year-ago quarter.
Revenues climbed 6.1% annually to $7.48 billion, exceeding Wall Street estimates. Organic revenue grew 7.5%. In the US market, revenues moved up 8.3%, while the non-US developed market registered a 1.8% growth. Emerging market revenue was 7.3% higher compared to the second quarter of 2018.
Revenues of the Cardiac and Vascular Group rose 3.1% year-on-year and those of Minimally Invasive Therapies Group moved up 4.9%. Restorative Therapies Group revenue was 7% higher compared to last year, while Diabetes Group surged 26%.
“This was an outstanding quarter for Medtronic. We are executing on multiple fronts, resulting in robust top-line growth, solid margin expansion, and increasing free cash flow. Yet, even more exciting than our results this quarter is the progress we are making on our new product pipeline, which is stronger than at any time in our company’s history,” said CEO Omar Ishrak.
The company revised up its full-year 2019 organic revenue growth outlook to the range of 5% to 5.5% from the earlier outlook of 4.5-5%. Maintaining the adjusted earnings per share outlook in the $5.10-$5.15 per share range, the management said it expects to absorb incremental expenses in the later part of the year, mainly those related to foreign exchange, China tariffs and the pending buyout of medical robotics company Mazor.
Medtronic shares reached a peak in mid-September but pared a part of the grains in the following weeks. The stock grew 8% since the beginning of the year, outperforming the S&P 500, and continued the uptrend after Tuesday’s earnings report.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%